News | May 18, 2025
Hikal posts Q4 FY25 consolidated PAT at Rs. 50 Cr
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
_256_384.jpg)
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA
Bayer expects 2025 to be the most difficult year of its turnaround
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
Strengthening capabilities in Peptide Therapeutics and CDMO services
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
Subscribe To Our Newsletter & Stay Updated
